BROOKS LABORATORIES LTD. - 533543 - Notice Of 20Th AGM Of Brooks Laboratories Limited
Notice of 20th AGM of Brooks Laboratories Limited to be held on 29th September, 202207-09-2022
07-09-2022
BROOKS LABORATORIES LTD. - 533543 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of the 20th Annual General Meeting of Brooks Laboratories Limited07-09-2022
BROOKS LABORATORIES LTD. - 533543 - Reg. 34 (1) Annual Report.
20th Annual report along with AGM notice of Brooks Laboratories Limited .06-09-2022
BROOKS LABORATORIES LTD. - 533543 - Board Meeting Outcome for To Increase The Authorised Share Capital Of The Company.
To increase the Authorised share capital of the Company.03-09-2022
BROOKS LABORATORIES LTD. - 533543 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Update under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements, 2015) regarding approval for Meropenem Injection 500mg per vial and 1gram per vial (the product) from the United States Food & Drug Administration (USFDA)21-08-2022
BROOKS LABORATORIES LTD. - 533543 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of financials for the quarter ended 30.06.202212-08-2022
BROOKS LABORATORIES LTD. - 533543 - Board Took Note Of The Payment Of Penalty Impose By The Exchange On The Company.
Board took note of the payment of penalty impose by the exchange on the Company.10-08-2022
BROOKS LABORATORIES LTD. - 533543 - Financial Results For 30Th June 2022
Financial results for 30th June 202210-08-2022
BROOKS LABORATORIES LTD. - 533543 - Board Meeting Outcome for Financial Results For 1St Quarter Ended 30.06.2022
financial results for 1st quarter ended 30.06.202210-08-2022
BROOKS LABORATORIES LTD. - 533543 - Board Meeting Intimation for Approval Of Unaudited Standalone And Consolidated Financial Results For The 1St Quarter Ended 30.06.2022.
BROOKS LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2022 ,inter alia, to consider and approve Unaudited Standalone and Consolidated financial results for the 1st Quarter ended 30.06.2022.03-08-2022